Emery P, Horton S, Dumitru RB, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Ann Rheum Dis 2020;79:464–71.
Abstract: results section, line 6 should read as “PD was fully suppressed by week 48 in 74-87%…” as opposed to currently stated “PD was fully suppressed by week 48 in over 90%…“
Results and ‘Imaging outcomes’, para 2:
line 3: This should read “Over 60% in each arm…” as opposed to “Over 50% in each arm…”
line 4–5 should read, “….by week 12 to 24%–37% in each arm, further reduced to 13%–26% by week 48…” as opposed to “….by week 12% to 15% in each arm, maintained by week 48…”
Discussion, para 4, line two should read “…US PD suppressed in both arms to 13%–26%…” as opposed to “…US PD suppressed in both arms to <13%…”
Table 1 (baseline characteristics) and table 4 (Total grey scale and Power Doppler ultrasound scores) have been updated with the correct values.
Table 1.
Baseline demographics and disease profile for the entire group, ETN+MTX and MTX-TT
| Variable | All | ETN+MTX | MTX-TT |
| Demographics | |||
| Age, years Mean (SD) | 50.0 (12.8) | 49.6 (12.5) | 50.3 (13.2) |
| Female % (n/N) | 71% (85) | 65% (39) | 77% (46) |
| RA presenting history, % (n/N) (unless otherwise stated) | |||
| Symptom duration, weeks, median (Q1, Q3) | 20.3 (13.1, 30.8) | 19.2 (12.5, 28.1) | 20.8 (15.9, 31.9) |
| Previous IM steroid | 1% (1/120) | 0% (0/60) | 2% (1/60) |
| Previous IA steroid | 0% (0/120) | 0% (0/60) | 0% (0/60) |
| Concomitant oral steroid | 3% (3/120) | 0% (0/60) | 5% (3/60) |
| Concomitant NSAID | 88% (105/120) | 92% (55/60) | 83% (50/60) |
| RA disease phenotype, % (n/N) | |||
| RF positive | 73% (87/120) | 70% (42/60) | 75% (45/60) |
| ACPA positive | 84% (101/120) | 82% (49/60) | 87% (52/60) |
| ANA positive | 15% (18/120) | 18% (11/60) | 12% (7/60) |
| RA disease activity components, Median (Q1, Q3) (unless otherwise stated) | |||
| TJC28 | 11.0 (7.0, 17.0) | 11.5 (6.0, 20.0) | 10.0 (7.0, 16.0) |
| SJC28 | 5.0 (2.0, 9.0) | 5.0 (3.0, 10.5) | 5.0 (2.0, 9.0) |
| ESR, mm/hr | 31.5 (18.5, 51.0) | 30.5 (17.0, 51.5) | 32.5 (20.5, 51.0) |
| CRP, mg/L | 8.8 (2.3, 24.0) | 10.2 (1.8, 28.0) | 8.0 (2.7, 21.5) |
| Disease activity VAS, mm Mean (SD) | 57.1 (22.3) | 60.7 (21.6) | 53.6 (22.6) |
| RA disease activity scores, Mean (SD) | |||
| DAS28-ESR | 5.7 (1.1) | 5.8 (1.1) | 5.6 (1.0) |
| DAS44-ESR | 3.7 (0.8) | 3.7 (0.9) | 3.7 (0.7) |
| DAS28-CRP | 5.1 (1.2) | 5.2 (1.2) | 4.9 (1.1) |
| DAS44-CRP | 3.4 (0.8) | 3.5 (0.9) | 3.3 (0.8) |
| SDAI | 31.6 (13.7) | 34.2 (14.7) | 29.0 (12.3) |
| CDAI | 29.8 (12.7) | 32.2 (13.6) | 27.3 (11.2) |
| Patient-reported outcome measures, Mean (SD) (unless otherwise stated) | |||
| Global pain VAS, mm | 53.5 (24.5) | 59.0 (23.4) | 48.1 (24.6) |
| HAQ-DI | 1.2 (0.5) | 1.2 (0.5) | 1.1 (0.5) |
| RAQoL | 17.3 (7.3) | 16.8 (7.4) | 17.9 (7.2) |
| In paid work % (n/N) | 73% (88/120) | 82% (49/60) | 65% (39/60) |
| EQ5D-3L index | 0.5 (0.3) | 0.4 (0.3) | 0.5 (0.3) |
| RAWIS | 18.2 (6.6) | 19.0 (6.7) | 17.3 (6.4) |
| Ultrasound scores Median (Q1, Q3) | |||
| Total GS score | 4.0 (2.0, 6.0) | 34.0 (2.0, 7.0) | 3. 5 (1.05, 6.0) |
| Total PD score | 2.0 (0.0, 4.0) | 2.0 (0.0, 4.05) | 02.0 (0.0, 3.0) |
| Total erosion score | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) |
| Radiographic score Median (Q1, Q3) | |||
| Total modified Sharp score | 2.5 (0.5, 6.0) | 2.0 (0.5, 5.0) | 2.5 (0.5, 6.3) |